Form 8-K - Current report:
SEC Accession No. 0001437749-24-031133
Filing Date
2024-10-11
Accepted
2024-10-11 16:53:01
Documents
16
Period of Report
2024-10-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nrxp20241011_8k.htm   iXBRL 8-K 57325
2 EXHIBIT 99.1 ex_731701.htm EX-99.1 34078
7 logolg.jpg GRAPHIC 12860
  Complete submission text file 0001437749-24-031133.txt   274440

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nxrp-20241007.xsd EX-101.SCH 3912
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nxrp-20241007_def.xml EX-101.DEF 13857
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nxrp-20241007_lab.xml EX-101.LAB 18279
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nxrp-20241007_pre.xml EX-101.PRE 13889
18 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20241011_8k_htm.xml XML 4954
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 241368064
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)